Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:192 (24 July), doi:10.1136/bmj.329.7459.192
Fiona Fleck
Geneva
| The first 150 words of the full text of this article appear below. |
The United States has come under fire for pressuring developing countries to give up their right to produce cheap, generic anti-AIDS medicines in return for bilateral trade agreements that strengthen protection of costlier, brand name drugs.
Nobel economics laureate Joseph Stiglitz joined advocacy groups Oxfam and Médecins Sans Frontières this month in criticising Washington for bowing to industry pressure by pursuing a policy the groups say could prevent millions of AIDS patients in poor countries from getting the lifesaving antiretroviral drugs and treatment they need.
US officials denied their trade policy was hampering the fight against AIDS, citing international trade rules that allow flexibility when poor countries face a health crisis.
Of an estimated 38 million people infected with HIV globally, less than 10% have access to antiretroviral drugs, and many of those are in wealthy, developed countries.
In a report released at an international AIDS conference in Bangkok this
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+